CoChat

Viloxazine: Pediatric First Approval

Open access
Lamb, Yvette N. · 2021 · Pediatric Drugs

The DOI matches its Crossref record; 11 of the 12 references it cites were found in a registry or an index.

Abstract

), a selective norepinephrine reuptake inhibitor, is being developed by Supernus Pharmaceuticals as a non-stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. This is a novel formulation of a pharmacological agent formerly marketed in Europe for the treatment of depression in adults. Viloxazine received its first pediatric approval in April 2021 in the USA for the treatment of ADHD in pediatric patients aged 6-17 years. Approval was based on positive results from a series of short-term phase III clinical trials in which viloxazine improved the severity of ADHD symptoms in children and adolescents with diagnosed ADHD. Viloxazine is available as extended-release capsules for once-daily oral administration. This article summarizes the milestones in the development of viloxazine leading to this first pediatric approval for ADHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40272-021-00453-3

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

Key milestones in the development of viloxazine, focusing on its use in the treatment of pediatric pts with ADHD. ADHD attention-deficit/hyperactivity disorder, CRL Complete Response Letter, NDA New Drug Application, pts patients
Key milestones in the development of viloxazine, focusing on its use in the treatment of pediatric pts with ADHD. ADHD attention-deficit/hyperactivity disorder, CRL Complete Response Letter, NDA New Drug Application, pts patientsCC BY-NC · PubMed Central
Viloxazine chemical structure
Viloxazine chemical structureCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 1

  1. Nasser A Hull JT Chowdhry FA Extended-release viloxazine (SPN-812) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents: topline results of a phase 3, randomized, double-blind, placebo-controlled study (P302) [abstract and poster] Neurotherapeutics 2019 16 3 914 915

Cited by

See all 31

Metadata

Authors
Lamb, Y. N.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Lamb, Yvette N.
Venue
Pediatric Drugs
Published
2021-05-26
Volume
23
Issue
4
Pages
403-409
ISSN
  • 1174-5878 (ISSN-L)
  • 1179-2019
OpenAlex
W3165290393
Cited by
29
References
12
Citations by year
2026: 1 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 2
FWCI
4.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Pediatric Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
viloxazine, attention deficit hyperactivity disorder, pediatric drug approval, norepinephrine reuptake inhibitors, sustained-release formulation, drug development milestones
MeSH terms
Administration, Oral, Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Humans, United States, Viloxazine, Drug Approval, Clinical Trials, Phase III as Topic, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Viloxazine: Pediatric First Approval. https://app.cochat.ai/papers/10.1007/s40272-021-00453-3
The paper
Lamb, Y. N. (2021). Viloxazine: Pediatric First Approval. Pediatric Drugs. https://doi.org/10.1007/s40272-021-00453-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.